Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + partial enteral nutrition
- Development stage
- Preclinical
- Lead developer
- Tongji Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Fecal microbiota transplantation (FMT) combined with partial enteral nutrition (PEN) is an investigational combination therapy being evaluated by Tongji Hospital for the treatment of active pediatric Crohn's disease. FMT involves the administration of processed stool from healthy donors to restore microbial diversity and stable community structure in the recipient's gut. PEN is a dietary strategy where a significant portion of caloric needs is met through specialized enteral formulas, supplemented by a restricted diet. This dual approach aims to induce clinical remission by correcting dysbiosis and reducing exposure to dietary antigens that may trigger intestinal inflammation. The therapy is being explored as a potential first-line treatment to avoid or delay the use of systemic immunosuppressive agents in children.
- Other names
- FMT + PENRepeated and multiple fecal microbiota transplantations plus partial enteral nutrition
Beyond the preview
Go deeper on fecal microbiota transplantation + partial enteral nutrition.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + partial enteral nutrition.